Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_4
1
25%
Ph phase_2
1
25%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
completed

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

NCT03694392
terminatedphase_4

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

NCT05514002
terminatedphase_2

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
completedphase_3

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

NCT02290509

Clinical Trials (4)

Showing 4 of 4 trials
NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Completed
NCT05514002Phase 4

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

Terminated
NCT03658629Phase 2

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Terminated
NCT02290509Phase 3

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4